Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 209 articles:
HTML format



Single Articles


    February 2021
  1. DU L, Yau C, Brown-Swigart L, Gould R, et al
    Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.
    Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00128.
    PubMed     Abstract available


  2. AGOSTINETTO E, Ignatiadis M
    Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: Lessons from the PEARL study.
    Ann Oncol. 2021 Feb 8. pii: S0923-7534(21)00106.
    PubMed    


  3. BRUFSKY A, Kim SB, Zvirbule Z, Eniu A, et al
    A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
    Ann Oncol. 2021 Feb 1. pii: S0923-7534(21)00093.
    PubMed     Abstract available


  4. MATIKAS A, Foukakis T
    SOLAR1s: alpelisib returns to earth?
    Ann Oncol. 2021;32:129-132.
    PubMed    


  5. VANACKER H, Cassier PA, Bachelot T
    The complex balance of PI3K inhibition.
    Ann Oncol. 2021;32:127-128.
    PubMed    


    January 2021
  6. CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
    Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
    PubMed     Abstract available


  7. DENKERT C, Untch M, Benz S, Schneeweiss A, et al
    Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
    Ann Oncol. 2021 Jan 5. pii: S0923-7534(20)43224.
    PubMed     Abstract available


    December 2020
  8. LOHMANN AE, Goodwin PJ
    Diabetes, metformin and breast cancer: a tangled web.
    Ann Oncol. 2020 Dec 31. pii: S0923-7534(20)43222.
    PubMed    


  9. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
    Ann Oncol. 2020 Dec 29. pii: S0923-7534(20)43221.
    PubMed     Abstract available


  10. PARK YM, Bookwalter DB, O'Brien KM, Jackson CL, et al
    A Prospective Study of Type 2 diabetes, metformin use, and risk of breast cancer.
    Ann Oncol. 2020 Dec 19. pii: S0923-7534(20)43214.
    PubMed     Abstract available


  11. FRANZOI MA, Romano E, Piccart M
    Immunotherapy for early breast cancer: too soon, too superficial, or just right?
    Ann Oncol. 2020 Dec 8. pii: S0923-7534(20)43198.
    PubMed     Abstract available


  12. GRINSHPUN A, Moss J, Uziely B
    Key Role for Liquid Biopsy in the Elimination of Breast Cancer Surgery following Neoadjuvant Therapy.
    Ann Oncol. 2020 Dec 7. pii: S0923-7534(20)43201.
    PubMed    


  13. AMIRI-KORDESTANI L, Xie D, Tolaney SM, Bloomquist E, et al
    A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
    Ann Oncol. 2020;31:1704-1708.
    PubMed     Abstract available


    November 2020
  14. ANDRE F, Ciruelos EM, Juric D, Loibl S, et al
    Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
    Ann Oncol. 2020 Nov 24. pii: S0923-7534(20)43166.
    PubMed     Abstract available


  15. EIKESDAL HP, Yndestad S, Elzawahry A, Llop-Guevara A, et al
    Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    Ann Oncol. 2020 Nov 23. pii: S0923-7534(20)43164.
    PubMed     Abstract available


  16. MAGBANUA MJM, Swigart LB, Wu HT, Hirst GL, et al
    Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Ann Oncol. 2020 Nov 21. pii: S0923-7534(20)43162.
    PubMed     Abstract available


  17. XU B, Sun T, Zhang Q, Zhang P, et al
    Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial.
    Ann Oncol. 2020 Nov 11. pii: S0923-7534(20)43130.
    PubMed     Abstract available


  18. DENT S, Cortes J, Im YH, Dieras V, et al
    Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Ann Oncol. 2020 Nov 10. pii: S0923-7534(20)43124.
    PubMed     Abstract available


  19. PUSZTAI L
    PARP inhibition in homologous recombination deficient early stage breast cancer.
    Ann Oncol. 2020 Nov 9. pii: S0923-7534(20)43128.
    PubMed    


    October 2020
  20. FASCHING PA, Link T, Hauke J, Seither F, et al
    Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42963.
    PubMed     Abstract available


  21. SIPOS O, Tovey H, Quist J, Haider S, et al
    Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42977.
    PubMed     Abstract available


  22. STECKLEIN SR, Sharma P
    Last but not Least: Antibody-Drug Conjugates in Hormone Receptor-Positive Metastatic Breast Cancer.
    Ann Oncol. 2020 Oct 7. pii: S0923-7534(20)42492.
    PubMed    


  23. LIN NU
    Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases.
    Ann Oncol. 2020;31:1279-1281.
    PubMed    


    September 2020
  24. GRINDA T, Delaloge S
    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42468.
    PubMed    


  25. CARDOSO F, Paluch-Shimon S, Senkus E, Curigliano G, et al
    5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(dagger).
    Ann Oncol. 2020 Sep 23. pii: S0923-7534(20)42460.
    PubMed    


  26. KALINSKY K, Diamond JR, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.
    Ann Oncol. 2020 Sep 15. pii: S0923-7534(20)42445.
    PubMed     Abstract available


  27. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220.
    Ann Oncol. 2020 Sep 7. pii: S0923-7534(20)42223.
    PubMed    


  28. KARN T, Denkert C, Weber KE, Holtrich U, et al
    Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
    Ann Oncol. 2020;31:1216-1222.
    PubMed     Abstract available


    August 2020
  29. LITTON JK, Hurvitz SA, Mina LA, Rugo HS, et al
    Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Ann Oncol. 2020 Aug 20. pii: S0923-7534(20)42106.
    PubMed     Abstract available


  30. MAYER EL, Abramson V, Jankowitz R, Falkson C, et al
    TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
    Ann Oncol. 2020 Aug 13. pii: S0923-7534(20)42061.
    PubMed     Abstract available


    July 2020
  31. LUEN SJ, Asher R, Lee CK, Savas P, et al
    Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39934.
    PubMed     Abstract available


  32. MONTEMURRO F, Delaloge S, Barrios CH, Wuerstlein R, et al
    Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.
    Ann Oncol. 2020 Jul 4. pii: S0923-7534(20)39930.
    PubMed     Abstract available


  33. LYMAN GH, Kuderer NM
    Personalized cancer supportive care in COVID-19 era.
    Ann Oncol. 2020;31:835-837.
    PubMed    


    May 2020
  34. HEIL J, Pfob A
    Patients should be the tipping point of individualizing breast cancer surgery.
    Ann Oncol. 2020 May 28. pii: S0923-7534(20)39844.
    PubMed    


  35. BARCENAS CH, Hurvitz SA, Di Palma JA, Bose R, et al
    Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.
    Ann Oncol. 2020 May 25. pii: S0923-7534(20)39833.
    PubMed     Abstract available


  36. METZGER O, Leone JP, Li T, Tan-Wasielewski Z, et al
    Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
    Ann Oncol. 2020 May 24. pii: S0923-7534(20)39835.
    PubMed     Abstract available


  37. HILBERS FS, Aftimos P
    Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?
    Ann Oncol. 2020 May 15. pii: S0923-7534(20)39818.
    PubMed    


  38. RUGO HS, Andre F, Yamashita T, Cerda H, et al
    Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.
    Ann Oncol. 2020 May 13. pii: S0923-7534(20)39798.
    PubMed     Abstract available


  39. CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
    European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
    Ann Oncol. 2020;31:650-658.
    PubMed     Abstract available


    April 2020
  40. ROSS DS, Liu B, Schram AM, Razavi P, et al
    Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients.
    Ann Oncol. 2020 Apr 26. pii: S0923-7534(20)39306.
    PubMed     Abstract available


  41. CABALLERO C, Piccart M
    Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.
    Ann Oncol. 2020 Apr 25. pii: S0923-7534(20)39307.
    PubMed    


  42. CLEMONS M, Fergusson D, Simos D, Mates M, et al
    A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
    Ann Oncol. 2020 Apr 20. pii: S0923-7534(20)39296.
    PubMed     Abstract available


    March 2020
  43. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 4(rd) International Consensus Guidelines for Breast Cancer in Young Women (BCY4).
    Ann Oncol. 2020 Mar 18. pii: S0923-7534(20)36363.
    PubMed     Abstract available


  44. GRELLETY T, Peyraud F, Sevenet N, Tredan O, et al
    Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
    Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362.
    PubMed    


  45. VAN DONGEN M, Kok M
    Mise en place: towards neoadjuvant chemo-immunotherapy for early triple-negative breast cancer.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36075.
    PubMed    


  46. MURPHY N, Knuppel A, Papadimitriou N, Martin RM, et al
    Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with approximately 430 000 women.
    Ann Oncol. 2020 Mar 9. pii: S0923-7534(20)36019.
    PubMed     Abstract available


  47. MAVROUDIS D, Saloustros E, Malamos N, Kakolyris S, et al
    Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volu
    Ann Oncol. 2020;31:444-445.
    PubMed    


  48. MOSS J, Zick A, Grinshpun A, Carmon E, et al
    Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer.
    Ann Oncol. 2020;31:395-403.
    PubMed     Abstract available


  49. BARROSO-SOUSA R, Jain E, Cohen O, Kim D, et al
    Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Ann Oncol. 2020;31:387-394.
    PubMed     Abstract available


  50. MOSELE F, Stefanovska B, Lusque A, Tran Dien A, et al
    Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Ann Oncol. 2020;31:377-386.
    PubMed     Abstract available


  51. DI COSIMO S, Appierto V, Silvestri M, Ortolan E, et al
    Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast.
    Ann Oncol. 2020;31:435-437.
    PubMed    


  52. YVER A, Agatsuma T, Soria JC
    The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
    Ann Oncol. 2020;31:430-434.
    PubMed    


  53. KURZROCK R, Bowles DW, Kang H, Meric-Bernstam F, et al
    Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Ann Oncol. 2020;31:412-421.
    PubMed     Abstract available


    February 2020
  54. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36026.
    PubMed    


  55. ADAMS S, Dieras V, Barrios CH, Winer EP, et al
    Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36038.
    PubMed     Abstract available


  56. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available


  57. SCHMID P, Salgado R, Park YH, Munoz-Couselo E, et al
    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Ann Oncol. 2020 Feb 14. pii: S0923-7534(20)36032.
    PubMed     Abstract available


  58. GRYNBERG M, Mayeur Le Bras A, Hesters L, Gallot V, et al
    First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer.
    Ann Oncol. 2020 Feb 12. pii: S0923-7534(20)35923.
    PubMed    


  59. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.
    Ann Oncol. 2020;31:283-288.
    PubMed     Abstract available


    January 2020
  60. PARK YH, Senkus-Konefka E, Im SA, Pentheroudakis G, et al
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35929.
    PubMed     Abstract available


  61. HEIL J, Kuerer HM, Pfob A, Rauch G, et al
    Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
    Ann Oncol. 2020;31:61-71.
    PubMed     Abstract available


    December 2019
  62. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Abstract available


  63. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Abstract available


  64. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Abstract available


  65. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x3-x11.
    PubMed     Abstract available


  66. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30 Suppl 10:x27-x42.
    PubMed     Abstract available


  67. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x12-x20.
    PubMed     Abstract available


  68. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019;30:2011.
    PubMed    


  69. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple-negative breast cancer and identifies patients with intrinsically good prognosis: have we been bringing owls to Athens?
    Ann Oncol. 2019;30:1849-1850.
    PubMed    


    November 2019
  70. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019;30:1842.
    PubMed    


  71. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019;30:1784-1795.
    PubMed     Abstract available


  72. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Ann Oncol. 2019;30:1776-1783.
    PubMed     Abstract available


  73. BRANDAO M, Coens C, Ignatiadis M
    Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?
    Ann Oncol. 2019;30:1677-1681.
    PubMed    


    October 2019
  74. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple negative breast cancer, and identifies patients with intrinsically good prognosis: Have we been bringing owls to Athens?
    Ann Oncol. 2019 Oct 18. pii: 5593649. doi: 10.1093.
    PubMed    


  75. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019 Oct 8. pii: 5583691. doi: 10.1093.
    PubMed     Abstract available


  76. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019;30:1674.
    PubMed    


  77. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
    Ann Oncol. 2019;30:1541-1557.
    PubMed     Abstract available


  78. ARNEDOS M, Gligorov J
    St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019;30:1533-1535.
    PubMed    


    August 2019
  79. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and Prediction of Benefit from Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen - To Offer More? (aTTom) Trial.
    Ann Oncol. 2019 Aug 28. pii: 5555808. doi: 10.1093.
    PubMed     Abstract available


  80. ARNEDOS M, Gligorov J
    St Gallen international consensus guidelines in early breast cancer: Experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019 Aug 27. pii: 5555359. doi: 10.1093.
    PubMed    


  81. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019 Aug 13. pii: 5549411. doi: 10.1093.
    PubMed    


  82. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548997. doi: 10.1093.
    PubMed    


  83. SRINIVASALU VK, Susan A, Philip A, Jose WM, et al
    147P Clinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543073. doi: 10.1093.
    PubMed    


  84. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.
    Ann Oncol. 2019 Aug 2. pii: 5543097. doi: 10.1093.
    PubMed     Abstract available


  85. SRINIVASALU VK, Susan A, Jose WM, Philip A, et al
    41P Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543072. doi: 10.1093.
    PubMed    


    July 2019
  86. LOI S
    The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.
    Ann Oncol. 2019 Jul 9. pii: 5530161. doi: 10.1093.
    PubMed    


  87. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017".
    Ann Oncol. 2019;30:1181.
    PubMed    


  88. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab".
    Ann Oncol. 2019;30:1180.
    PubMed    


  89. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Corrections to "Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis".
    Ann Oncol. 2019;30:1179.
    PubMed    


  90. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple-negative breast cancer.
    Ann Oncol. 2019;30:1051-1060.
    PubMed     Abstract available


  91. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019;30:1044-1050.
    PubMed     Abstract available


  92. FOULKES WD, Polak P
    Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019;30:1023-1025.
    PubMed    


    June 2019
  93. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 24. pii: 5522519. doi: 10.1093.
    PubMed    


  94. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 4. pii: 5499075. doi: 10.1093.
    PubMed    


    May 2019
  95. OLIVEIRA M, Saura C, Nuciforo P, Calvo I, et al
    FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
    Ann Oncol. 2019 May 30. pii: 5506637. doi: 10.1093.
    PubMed     Abstract available


  96. LOIBL S, Untch M, Burchardi N, Huober J, et al
    A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
    Ann Oncol. 2019 May 16. pii: 5490226. doi: 10.1093.
    PubMed     Abstract available


  97. FOULKES WD, Polak P
    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019 May 15. pii: 5489599. doi: 10.1093.
    PubMed    


  98. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
    Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
    PubMed    


  99. MARSDEN J, Hamoda H
    European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al. (Ann Oncol 2019; 30: doi.org/10.1093/annonc/mdz051).
    Ann Oncol. 2019 May 9. pii: 5482565. doi: 10.1093.
    PubMed    


  100. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple negative breast cancer.
    Ann Oncol. 2019 May 3. pii: 5485241. doi: 10.1093.
    PubMed     Abstract available


  101. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019;30:781-787.
    PubMed     Abstract available


  102. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019;30:774-780.
    PubMed     Abstract available


  103. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019;30:766-773.
    PubMed     Abstract available


    April 2019
  104. DE AZAMBUJA E, Piccart-Gebhart M
    ER+/HER2+ breast cancer: are we really de-escalating?
    Ann Oncol. 2019 Apr 16. pii: 5472336. doi: 10.1093.
    PubMed    


  105. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019 Apr 9. pii: 5435960. doi: 10.1093.
    PubMed     Abstract available


  106. MARRA A, Curigliano G
    T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.
    Ann Oncol. 2019 Apr 2. pii: 5425459. doi: 10.1093.
    PubMed    


  107. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Ann Oncol. 2019;30:567-574.
    PubMed     Abstract available


  108. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019;30:558-566.
    PubMed     Abstract available


    March 2019
  109. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2019 Mar 30. pii: 5423828. doi: 10.1093.
    PubMed    


  110. MESSAOUDENE M, Mourikis TP, Michels J, Fu Y, et al
    T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.
    Ann Oncol. 2019 Mar 29. pii: 5423181. doi: 10.1093.
    PubMed     Abstract available


  111. VEERARAGHAVAN J, De Angelis C, Mao R, Wang T, et al
    A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Ann Oncol. 2019 Mar 23. pii: 5418530. doi: 10.1093.
    PubMed     Abstract available


  112. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019 Mar 19. pii: 5382368. doi: 10.1093.
    PubMed     Abstract available


  113. HREBIEN S, Citi V, Garcia-Murillas I, Cutts R, et al
    Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.
    Ann Oncol. 2019 Mar 12. pii: 5376514. doi: 10.1093.
    PubMed     Abstract available


  114. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019 Mar 12. pii: 5376517. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  115. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019 Feb 23. pii: 5364015. doi: 10.1093.
    PubMed     Abstract available


  116. GUARNERI V, Dieci MV, Bisagni G, Frassoldati A, et al
    De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.
    Ann Oncol. 2019 Feb 18. pii: 5332974. doi: 10.1093.
    PubMed     Abstract available


  117. TELLI ML, Vinayak S
    Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
    Ann Oncol. 2019 Feb 7. pii: 5308591. doi: 10.1093.
    PubMed    


  118. YAP YS, Ho D, Ng RC, Chan CH, et al
    27PDetection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30.
    PubMed    


  119. SON S, Kim H, Shin I
    23PMatricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed    


  120. KIM H, Son S
    22PTherapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed    


  121. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Ann Oncol. 2019;30:236-242.
    PubMed     Abstract available


  122. KIM H, Son S
    Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed    


  123. SON S, Kim H, Shin I
    Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    PubMed    


  124. YAP YS, Ho D, Ng RC, Chan CH, et al
    Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30 Suppl 1:i10.
    PubMed    


    January 2019
  125. CONDORELLI R, Mosele F, Verret B, Bachelot T, et al
    Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Ann Oncol. 2019 Jan 31. pii: 5305018. doi: 10.1093.
    PubMed     Abstract available


  126. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019 Jan 23. pii: 5299440. doi: 10.1093.
    PubMed     Abstract available


  127. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.
    Ann Oncol. 2019 Jan 23. pii: 5299438. doi: 10.1093.
    PubMed     Abstract available


  128. DIECI MV, Conte P, Bisagni G, Brandes AA, et al
    Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Ann Oncol. 2019 Jan 17. pii: 5290085. doi: 10.1093.
    PubMed     Abstract available


  129. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
    Ann Oncol. 2019 Jan 9. pii: 5281258. doi: 10.1093.
    PubMed    


  130. BASELGA J, Manikhas A, Cortes J, Llombart A, et al
    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281256. doi: 10.1093.
    PubMed    


  131. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281259. doi: 10.1093.
    PubMed    


  132. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281263. doi: 10.1093.
    PubMed    


  133. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2019 Jan 9. pii: 5281261. doi: 10.1093.
    PubMed    


  134. WU Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, et al
    Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281255. doi: 10.1093.
    PubMed    


    December 2018
  135. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy.
    Ann Oncol. 2018 Dec 27. pii: 5262220. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  136. ADAMS S, Schmid P, Rugo HS, Winer EP, et al
    Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209693. doi: 10.1093.
    PubMed     Abstract available


  137. ADAMS S, Loi S, Toppmeyer D, Cescon DW, et al
    Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209695. doi: 10.1093.
    PubMed     Abstract available


  138. EVRON E, Ben-David AM, Goldberg H, Fried G, et al
    Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer.
    Ann Oncol. 2018 Nov 23. pii: 5200725. doi: 10.1093.
    PubMed     Abstract available


  139. SOKOL ES, Feng YX, Jin DX, Basudan A, et al
    Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Ann Oncol. 2018 Nov 13. pii: 5181087. doi: 10.1093.
    PubMed     Abstract available


  140. FOUKAKIS T
    Carboplatin in the neoadjuvant treatment of triple-negative breast cancer - ready for prime time?
    Ann Oncol. 2018 Nov 5. pii: 5160131. doi: 10.1093.
    PubMed    


    October 2018
  141. MATHEW A, Erqou S
    Can Estrogen Receptor Status Predict for Shorter Duration of Adjuvant Trastuzumab in Early-Stage Breast Cancer?
    Ann Oncol. 2018 Oct 24. pii: 5144112. doi: 10.1093.
    PubMed    


  142. MATIKAS A, Foukakis T, Moebus V, Greil R, et al
    Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients.
    Ann Oncol. 2018 Oct 24. pii: 5144113. doi: 10.1093.
    PubMed     Abstract available


  143. KOK M, Winer E, Loi S
    Passion for Immune checkpoint blockade in triple negative breast cancer? Comment on the IMpassion130 study.
    Ann Oncol. 2018 Oct 23. pii: 5142540. doi: 10.1093.
    PubMed    


  144. COTTU P, D'Hondt V, Dureau S, Lerebours F, et al
    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Ann Oncol. 2018 Oct 11. pii: 5126820. doi: 10.1093.
    PubMed     Abstract available


  145. BRANDAO M, Ignatiadis M
    CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?
    Ann Oncol. 2018 Oct 10. pii: 5126228. doi: 10.1093.
    PubMed    


    September 2018
  146. SZEKELY B, Bossuyt V, Li X, Wali VB, et al
    Immunological differences between primary and metastatic breast cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094494. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  147. CHEN X, Li Y, Ouyang T, Li J, et al
    Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Ann Oncol. 2018 Aug 27. pii: 5079839. doi: 10.1093.
    PubMed     Abstract available


  148. ETTL J, Quek RGW, Lee KH, Rugo HS, et al
    Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ann Oncol. 2018 Aug 15. pii: 5074207. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  149. CARDOSO F, Senkus E, Costa A, Papadopoulos E, et al
    4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
    Ann Oncol. 2018 Jul 19. pii: 5055519. doi: 10.1093.
    PubMed    


  150. ROBSON M
    Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
    Ann Oncol. 2018 Jul 4. pii: 5048958. doi: 10.1093.
    PubMed    


    June 2018
  151. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Abstract available


  152. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2018 Jun 18. pii: 5039891. doi: 10.1093.
    PubMed     Abstract available


  153. ZHANG J, Lin Y, Sun XJ, Wang BY, et al
    Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037891. doi: 10.1093.
    PubMed     Abstract available


  154. IGNATIADIS M, Litiere S, Rothe F, Riethdorf S, et al
    Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.
    Ann Oncol. 2018 Jun 11. pii: 5035683. doi: 10.1093.
    PubMed     Abstract available


  155. MALORNI L, Curigliano G, Minisini AM, Cinieri S, et al
    Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
    Ann Oncol. 2018 Jun 11. pii: 5035682. doi: 10.1093.
    PubMed     Abstract available


  156. YARDLEY DA, Coleman R, Conte P, Cortes J, et al
    nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.
    Ann Oncol. 2018 Jun 6. pii: 5033593. doi: 10.1093.
    PubMed     Abstract available


  157. POGGIO F, Bruzzone M, Ceppi M, Ponde NF, et al
    Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Ann Oncol. 2018 Jun 4. pii: 5026316. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  158. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2018 May 3. pii: 4992289. doi: 10.1093.
    PubMed    


  159. GAGE MM, Mylander WC, Rosman M, Fujii T, et al
    Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Ann Oncol. 2018;29:1280-1285.
    PubMed     Abstract available


  160. LIU C, Wang L, Zhuang J, Liu L, et al
    Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
    Ann Oncol. 2018;29:1329-1330.
    PubMed    


    April 2018
  161. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2018 Apr 27. pii: 4989216. doi: 10.1093.
    PubMed     Abstract available


  162. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2018 Apr 26. pii: 4986930. doi: 10.1093.
    PubMed    


  163. GEFFEN DB
    Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
    Ann Oncol. 2018 Apr 4. pii: 4959909. doi: 10.1093.
    PubMed    


  164. CRUZ C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, et al
    RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.
    Ann Oncol. 2018 Apr 4. pii: 4959904. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  165. CORTES J, Perez-Garcia J, Levy C, Gomez Pardo P, et al
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Ann Oncol. 2018 Feb 21. pii: 4897992. doi: 10.1093.
    PubMed     Abstract available


  166. MARTIN M, Campone M, Bondarenko I, Sakaeva D, et al
    Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Ann Oncol. 2018 Feb 10. pii: 4852792. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  167. TAN WW, Hillman DW, Salim M, Northfelt DW, et al
    N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Ann Oncol. 2018 Jan 29. pii: 4829660. doi: 10.1093.
    PubMed    


  168. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    PubMed     Abstract available


  169. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    PubMed     Abstract available


  170. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    PubMed    


  171. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    PubMed     Abstract available


  172. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    PubMed     Abstract available


  173. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2018 Jan 2. pii: 4782676. doi: 10.1093.
    PubMed    


    December 2017
  174. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Abstract available


  175. SHARMA P, Barlow WE, Godwin AK, Pathak H, et al
    Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313).
    Ann Oncol. 2017 Dec 23. pii: 4774220. doi: 10.1093.
    PubMed     Abstract available


  176. SWAIN SM, Ewer MS, Viale G, Delaloge S, et al
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Ann Oncol. 2017 Dec 15. pii: 4748818. doi: 10.1093.
    PubMed     Abstract available


  177. CONDORELLI R, Spring L, O'Shaughnessy J, Lacroix L, et al
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Ann Oncol. 2017 Dec 11. pii: 4725051. doi: 10.1093.
    PubMed     Abstract available


  178. GENNARI A, Sun Z, Hasler-Strub U, Colleoni M, et al
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Ann Oncol. 2017 Dec 8. pii: 4710349. doi: 10.1093.
    PubMed     Abstract available


  179. PALUCH-SHIMON S, Peccatori FA
    BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
    Ann Oncol. 2017 Dec 5. pii: 4693825. doi: 10.1093.
    PubMed    


    November 2017
  180. FRANCIS PA
    Male Breast Cancer: Pink Ribbon Blues.
    Ann Oncol. 2017 Nov 20. doi: 10.1093.
    PubMed    


  181. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Abstract available


  182. SESTAK I, Smith SG, Howell A, Forbes JF, et al
    Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Ann Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Abstract available


  183. PATEL R, Maxwell S, Yan D, Dressler EV, et al
    Medical Oncologists' Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed    


    October 2017
  184. KOK M
    LAG-3: another brake to release in breast cancer?
    Ann Oncol. 2017 Oct 30. doi: 10.1093.
    PubMed    


  185. CARDOSO F, Bartlett JMS, Slaets L, van Deurzen CHM, et al
    Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Abstract available


  186. BLACKWELL K, Gascon P, Krendyukov A, Gattu S, et al
    Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppr
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Abstract available


  187. CRISCITIELLO C, Bayar MA, Curigliano G, Symmans FW, et al
    A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.
    Ann Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Abstract available


  188. MOBUS V, Jackisch C, Lueck HJ, du Bois A, et al
    Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann Oncol. 2017 Oct 24. doi: 10.1093.
    PubMed     Abstract available


  189. NUCIFORO P, Pascual T, Cortes J, Llombart-Cussac A, et al
    A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Ann Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Abstract available


  190. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


  191. LAMBERTINI M, Goldrat O, Ferreira AR, Dechene J, et al
    Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


  192. FRIBBENS C, Garcia Murillas I, Beaney M, Hrebien S, et al
    Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Ann Oncol. 2017 Oct 4. doi: 10.1093.
    PubMed     Abstract available


  193. FUJII T, Kogawa T, Dong W, Sahin AA, et al
    Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
    Ann Oncol. 2017;28:2420-2428.
    PubMed     Abstract available


    September 2017
  194. HAN HS, Dieras V, Robson M, Palacova M, et al
    Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Abstract available


  195. BURUGU S, Gao D, Leung S, Chia SK, et al
    LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Abstract available


  196. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed    


  197. KIROVA YM, Carroll S, Fourquet A, Offersen B, et al
    The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Ann Oncol. 2017 Sep 22. doi: 10.1093.
    PubMed    


  198. CHAJES V, Assi N, Biessy C, Ferrari P, et al
    A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Abstract available


  199. MESSINA C, Messina M, Zanardi E
    Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed    


  200. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed    


  201. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekl
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Abstract available


  202. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Abstract available


  203. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    PubMed     Abstract available


  204. BERNICHON E, Vallard A, Wang Q, Attignon V, et al
    Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Abstract available


  205. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    PubMed    


    August 2017
  206. CHUNG JH, Pavlick D, Hartmaier R, Schrock AB, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Ann Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  207. PRUNERI G, Lazzeroni M, Bagnardi V, Tiburzio GB, et al
    The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Ann Oncol. 2017;28:321-328.
    PubMed     Abstract available


  208. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Abstract available


  209. MAKKOUK A, Sundaram V, Chester C, Chang S, et al
    Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Ann Oncol. 2017;28:415-420.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: